- Home
- QIPT vs IMUX Comparison
QIPT vs IMUX Comparison
Compare QIPT & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QIPT
- IMUX
- Stock Information
- Founded
- QIPT 1993
- IMUX 2016
- Country
- QIPT United States
- IMUX United States
- Employees
- QIPT N/A
- IMUX N/A
- Industry
- QIPT
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- QIPT
- IMUX Health Care
- Exchange
- QIPT Nasdaq
- IMUX Nasdaq
- Market Cap
- QIPT 112.0M
- IMUX 102.2M
- IPO Year
- QIPT N/A
- IMUX N/A
- Fundamental
- Price
- QIPT $2.25
- IMUX $1.11
- Analyst Decision
- QIPT Strong Buy
- IMUX Strong Buy
- Analyst Count
- QIPT 2
- IMUX 7
- Target Price
- QIPT $6.50
- IMUX $12.67
- AVG Volume (30 Days)
- QIPT 125.2K
- IMUX 585.3K
- Earning Date
- QIPT 05-14-2025
- IMUX 05-07-2025
- Dividend Yield
- QIPT N/A
- IMUX N/A
- EPS Growth
- QIPT N/A
- IMUX N/A
- EPS
- QIPT N/A
- IMUX N/A
- Revenue
- QIPT $244,723,000.00
- IMUX N/A
- Revenue This Year
- QIPT $3.35
- IMUX N/A
- Revenue Next Year
- QIPT $5.39
- IMUX N/A
- P/E Ratio
- QIPT N/A
- IMUX N/A
- Revenue Growth
- QIPT 3.82
- IMUX N/A
- 52 Week Low
- QIPT $2.22
- IMUX $0.92
- 52 Week High
- QIPT $4.23
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- QIPT 36.51
- IMUX 47.35
- Support Level
- QIPT $2.22
- IMUX $1.18
- Resistance Level
- QIPT $2.42
- IMUX $1.28
- Average True Range (ATR)
- QIPT 0.10
- IMUX 0.07
- MACD
- QIPT 0.01
- IMUX -0.01
- Stochastic Oscillator
- QIPT 15.00
- IMUX 27.27
About QIPT Quipt Home Medical Corp.
Quipt Home Medical Corp provides in-home monitoring equipment, supplies, and services to patients. The Company operates in one business segment, which is the sale and rental of medical equipment and related devices. The company's services consist of Daily and Ambulatory Aides, Power Mobility, INR Self-Testing, Respiratory Equipment Rental, Home ventilation, Oxygen Therapy, and Sleep Apnea and PAP Treatment.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.